Quantum BioPharma Ltd. (NASDAQ: QNTM) has filed a supplement to its September 28, 2026, management information circular, correcting and restating the proposed special resolution that would authorize a consolidation of its Class A multiple voting shares and Class B subordinate voting shares. The clarification comes ahead of the company’s annual general and special meeting of shareholders scheduled for November 10, 2026.
Under the clarified terms, fractional shares equal to or less than one-half will be rounded down to the nearest whole share, while fractions greater than one-half will be rounded up. This standard rounding mechanism provides a clear framework for shareholders whose holdings may not divide evenly under the consolidation ratio. Importantly, the company also clarified that it will implement measures to cap the aggregate voting power of multiple voting shareholders at 70% if cancellations of Class B subordinate voting shares would otherwise cause that threshold to be exceeded. This safeguard is designed to prevent unintended shifts in control that could arise from the cancellation of subordinate voting shares.
The supplement is significant because it addresses potential ambiguities in the original resolution that could have led to confusion or disputes among shareholders. By restating the resolution with precise rounding rules and a voting power cap, Quantum BioPharma aims to ensure a transparent and orderly process for the consolidation. Previously submitted proxies will remain valid unless revoked or changed, and shareholders are encouraged to review the supplemental materials before the meeting. The company has directed investors to the full press release for complete details.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum also invented UNBUZZD™ and retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd Wellness Inc., with royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity.
The clarification of the consolidation terms matters to investors because share consolidations can materially affect the number of shares outstanding and, consequently, the market price and voting dynamics of the company. The 70% voting power cap specifically addresses the rights of multiple voting shareholders, ensuring that the consolidation does not inadvertently concentrate control beyond that threshold. For a company with a dual-class share structure, such safeguards are critical to maintaining balanced governance and protecting the interests of subordinate voting shareholders.
MissionIR, a specialized communications platform, has been assisting with syndicated content to enhance visibility of private and public companies. It is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and social media distribution among other services. For more information, visit MissionIR. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
